Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Tuvatexib Ointment Compared to Placebo for Patients with Actinic Keratosis

InvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is studying actinic keratosis, a skin condition where rough, scaly patches develop on areas of skin that have been exposed to the sun over many years, typically on the face or scalp. These patches occur when skin cells grow abnormally due to sun damage and can sometimes develop into skin cancer if left untreated. The study will test a treatment called VDA-1102 ointment, which contains the active ingredient tuvatexib, and compare it to placebo ointment to see which works better at treating these skin patches.

The purpose of this study is to find out how well VDA-1102 ointment works compared to placebo ointment in treating a specific marker patch of actinic keratosis after twelve weeks of treatment. The marker patch is chosen as the one showing the most abnormal cell growth activity at the start of the study. During the trial, patients will apply the ointment to a specific area of their skin that contains several of these rough patches. The study will use a special imaging technique called LC-OCT, which is a type of scan that allows doctors to look at the deeper layers of skin without cutting into it, to measure changes in the skin patches.

Throughout the study, doctors will track several things including how many of the skin patches clear up completely or partially, changes in how the marker patch looks under the imaging scan, and the overall appearance of the treated skin area. Patients will apply the treatment for a period of twelve weeks, and doctors will monitor for any unwanted effects or reactions on the skin. The study may also include an optional skin sample taken from the marker patch to examine the tissue more closely under a microscope to better understand how the treatment is working at the cellular level.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Treatment period begins

    The treatment phase starts after your enrollment in the trial. During this period, you will apply the assigned ointment to the designated treatment area on your face or scalp.

    The treatment area will contain between 4 and 8 individual skin lesions, including one specific lesion that has been identified as the marker lesion. This marker lesion is the one with the highest level of abnormal cell activity at the start of the study.

    You will be randomly assigned to receive either VDA-1102 ointment (containing the active substance tuvatexib) or a placebo ointment (which does not contain any active substance). Neither you nor the medical team will know which ointment you are receiving during the trial.

    The ointment should be applied topically, meaning directly onto the skin surface of the treatment area.

    This treatment period will last for 12 weeks.

  2. Step 2

    Regular monitoring visits

    Throughout the 12-week treatment period, you will attend scheduled visits for monitoring and assessment.

    During these visits, the medical team will examine the treatment area and the marker lesion using a specialized imaging technique called LC-OCT (a type of optical scan that allows visualization of skin layers without cutting the skin).

    The team will count the number of visible or touchable skin lesions in the treatment area to track changes over time.

    Your skin reactions in the treatment area will be assessed and recorded. This includes checking for any redness, scaling, crusting, swelling, or other local skin changes.

    Any side effects or health changes you experience will be documented as part of safety monitoring.

  3. Step 3

    Assessment at 12 weeks

    At the end of the 12-week treatment period, a comprehensive evaluation will be performed.

    The marker lesion will be examined again using LC-OCT to measure changes in abnormal cell activity. This measurement uses a modified PRO score, which assesses the degree of rapidly dividing cells in the deeper layers of the skin.

    The medical team will count all visible or touchable lesions in the treatment area to determine if there has been complete clearance (all lesions gone), partial clearance of 75% or more (at least three-quarters of lesions gone), or a different level of improvement.

    The cosmetic appearance of the treated area will be assessed and compared to how it looked at the beginning of the study.

    You may be asked to provide your assessment of the treatment product.

    In some cases, an optional biopsy (removal of a small tissue sample for laboratory examination) of the marker lesion may be performed for additional analysis.

  4. Step 4

    Safety monitoring throughout the trial

    Throughout the entire trial period, any adverse events or serious adverse events will be carefully monitored and recorded.

    Local skin reactions in the treatment area will be scored at each visit to track any irritation or other skin changes caused by the ointment application.

    The treatment area will be examined for any signs of squamous cell carcinoma (a type of skin cancer). If any suspicious lesions are identified, they will be biopsied and examined under a microscope to confirm or rule out this condition.

Who can join the trial?

8 criteria

  • You must provide written informed consent, which means you agree in writing to take part in the study before any study activities begin.
  • You must be 18 years of age or older.
  • You must have a confirmed diagnosis of actinic keratosis, which are rough, scaly patches on the skin caused by sun damage, on your face or scalp.
  • You must have an AKASI score of at least 3.0. AKASI is a measurement system that calculates how widespread and severe your actinic keratosis patches are by looking at the affected area and thickness of the patches.
  • You must have at least one actinic keratosis lesion, which is a rough skin patch, with a PRO score of 2 or higher on your scalp or face. The PRO score is a measurement taken using a special imaging device called LC-OCT, which is a type of scan that looks at the layers of your skin.
  • Among your actinic keratosis patches with the highest PRO scores, the study doctor must be able to choose one patch that is suitable to be used as a marker lesion, which is a specific patch that will be closely monitored throughout the study to measure how well the treatment works.
  • The area around the chosen marker lesion must contain between 4 to 8 separate actinic keratosis patches, including the marker lesion itself. This area will be used as the study treatment area and must not have any other conditions that would prevent you from participating.
  • You must be able and willing to apply the study medication as instructed and follow all study instructions reliably throughout the study period.

Who cannot join the trial?

4 criteria

  • The source data does not provide specific exclusion criteria (reasons why a patient cannot participate) for this clinical trial
  • Without detailed information about who should not join the study, it is not possible to list the specific conditions or situations that would prevent participation
  • The trial involves treatment with VDA-1102 ointment (a medication applied to the skin) for actinic keratosis (rough, scaly patches on the skin caused by sun damage)
  • The study accepts both male and female participants who are adults or elderly persons
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

VDA-1102 ointment is an investigational topical treatment being studied for actinic keratosis, which are rough, scaly patches on the skin caused by sun damage. This ointment is applied directly to the skin to see if it can help treat these precancerous skin lesions. The study will compare how well this ointment works against a placebo ointment that contains no active medicine.

What is already known about the treatment

VDA-1102 – VDA-1102 is an experimental ointment that is applied directly to the skin and is currently being tested in clinical trials for the treatment of actinic keratosis, which are rough, scaly patches on the skin caused by sun damage that can potentially develop into skin cancer. The medication works by targeting rapidly dividing skin cells at the molecular level to help eliminate these abnormal growths. This topical treatment is being evaluated to determine if it can effectively reduce or eliminate actinic keratosis lesions when applied regularly over a 12-week period, compared to an inactive placebo ointment.

Investigated diseases

Actinic Keratosis – Actinic keratosis is a skin condition that develops due to prolonged exposure to ultraviolet radiation from the sun or artificial sources. It appears as rough, scaly patches on sun-exposed areas of the body, most commonly on the face, scalp, ears, neck, forearms, and back of the hands. The patches are typically dry and may be skin-colored, pink, red, or brown. The lesions can vary in size from very small to several centimeters in diameter. Over time, the affected areas may become thicker and more prominent. The condition progresses slowly and multiple lesions often develop in the same general area.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2025-522482-30-00Protocol codeVDA-CP-06 P2BEstimated enrolment39 patientsSponsorVidac Pharma Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).